HS
HighVista Strategies Portfolio holdings
AUM
$272M
This Quarter Return
+1.03%
1 Year Return
+24.34%
3 Year Return
+176.43%
5 Year Return
+271.23%
10 Year Return
+682.63%
AUM
$269M
AUM Growth
+$269M
(-7.3%)
Cap. Flow
-$10.1M
Cap. Flow
% of AUM
-3.75%
Top 10 Holdings %
Top 10 Hldgs %
26.35%
Holding
168
New
26
Increased
41
Reduced
37
Closed
31
Top Buys
| 1 |
Meta Platforms (Facebook)
META
|
$3.1M |
| 2 |
Guardant Health
GH
|
$2.88M |
| 3 |
Janux Therapeutics
JANX
|
$2.48M |
| 4 |
Apellis Pharmaceuticals
APLS
|
$2.32M |
| 5 |
Dynavax Technologies
DVAX
|
$1.73M |
Top Sells
| 1 |
CTLT
CATALENT, INC.
CTLT
|
$4.58M |
| 2 |
Capri Holdings
CPRI
|
$3.3M |
| 3 |
Amgen
AMGN
|
$3.25M |
| 4 |
Maplebear
CART
|
$3.2M |
| 5 |
GE Vernova
GEV
|
$2.6M |
Sector Composition
| 1 | Healthcare | 43.86% |
| 2 | Technology | 16.73% |
| 3 | Consumer Discretionary | 7.18% |
| 4 | Communication Services | 5.42% |
| 5 | Industrials | 4.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
Adobe
ADBE
$148B
| $1.2M | 0.45% |
2,700
+900
| +50% | +$400K |
|
102
Caesars Entertainment
CZR
$5.18B
| $1.18M | 0.44% |
+35,200
| New | +$1.18M |
|
103
Core Scientific
CORZ
$4.15B
| $1.14M | 0.42% |
81,300
-51,500
| -39% | -$724K |
|
104
Arvinas
ARVN
$580M
| $1.11M | 0.41% |
58,001
| – | – |
|
|
VRNA
105
Verona Pharma
VRNA
$9.18B
| $1.1M | 0.41% |
23,739
| – | – |
|
106
Corbus Pharmaceuticals
CRBP
$119M
| $888K | 0.33% |
75,292
| – | – |
|
107
Praxis Precision Medicines
PRAX
$980M
| $843K | 0.31% |
10,951
| – | – |
|
108
Ascendis Pharma
ASND
$12.1B
| $836K | 0.31% |
+6,072
| New | +$836K |
|
109
Keros Therapeutics
KROS
$638M
| $825K | 0.31% |
52,107
| – | – |
|
|
CNTA
110
Centessa Pharmaceuticals
CNTA
$2.13B
| $772K | 0.29% |
46,116
| – | – |
|
111
Natera
NTRA
$23B
| $764K | 0.28% |
4,828
+1,388
| +40% | +$220K |
|
112
Xencor
XNCR
$594M
| $734K | 0.27% |
+31,942
| New | +$734K |
|
113
Ocular Therapeutix
OCUL
$2.25B
| $728K | 0.27% |
85,241
+20,214
| +31% | +$173K |
|
114
Terns Pharmaceuticals
TERN
$651M
| $726K | 0.27% |
130,966
| – | – |
|
115
Trip.com Group
TCOM
$46.6B
| $711K | 0.26% |
10,356
+800
| +8% | +$54.9K |
|
116
Dianthus Therapeutics
DNTH
$781M
| $684K | 0.25% |
31,387
+11,579
| +58% | +$252K |
|
117
Madrigal Pharmaceuticals
MDGL
$9.7B
| $682K | 0.25% |
2,211
| – | – |
|
118
Cytokinetics
CYTK
$5.98B
| $671K | 0.25% |
14,261
+4,206
| +42% | +$198K |
|
119
Krystal Biotech
KRYS
$4.35B
| $661K | 0.25% |
+4,217
| New | +$661K |
|
120
Soleno Therapeutics
SLNO
$3.56B
| $645K | 0.24% |
14,344
+3,259
| +29% | +$146K |
|
121
CG Oncology
CGON
$2.19B
| $640K | 0.24% |
22,305
+6,571
| +42% | +$188K |
|
|
ITCI
122
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $626K | 0.23% |
7,496
| – | – |
|
123
Structure Therapeutics
GPCR
$1.14B
| $476K | 0.18% |
17,561
-14,157
| -45% | -$384K |
|
124
Geron
GERN
$893M
| $451K | 0.17% |
127,284
| – | – |
|
125
Perspective Therapeutics
CATX
$251M
| $441K | 0.16% |
138,350
| – | – |
|